Dr. Lujun Zhao 赵路军
Chief Physician
Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation and multidisciplinary treatment for lung cancer, esophageal cancer, and thymoma. Focus includes pre- and post-operative adjuvant therapy and locally advanced inoperable cases.
Dr. Zhao holds a PhD in Oncology from Peking Union Medical College and completed postdoctoral training in radiation oncology at the University of Michigan Medical Center. With over 20 years of clinical experience, Dr. Zhao specializes in chest tumors. Research interests include stereotactic radiotherapy, intensity-modulated radiotherapy, and prevention of radiation-induced lung injury. Dr. Zhao has published over 100 papers.
Professional roles
- Chair, Radiation Oncology Branch, Tianjin Medical Association
- Standing Committee Member and Secretary-General, Professional Committee of Radiation Oncology, China Anti-Cancer Association
- Standing Committee Member, Radiation Oncology Branch, Chinese Medical Association
- Standing Committee Member, Non-Small Cell Lung Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Zhao Lujun). Papers usually list the name as Lujun Zhao or Zhao L.
Selected publications
153 papers on PubMed matched by name and affiliation; 35 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): Risk-adapted use of thoracic radiotherapy in stage IV non-small cell lung cancer: a multicenter prognostic model study. PubMed 42718716
- Front Immunol, 2026 (senior author): The effect of consolidation immunotherapy on patients with stage III non-small cell lung cancer who received induction chemoimmunotherapy: a multicenter retrospective study. PubMed 42131317
- Radiat Oncol, 2026 (senior author): Elective nodal irradiation of high-risk regions is superior to involved field radiotherapy for limited-stage small cell lung cancer: a propensity score-matched retrospective study. PubMed 42050661
- Front Oncol, 2026 (senior author): Comparison of long-term prognoses between 3D-printed template-guided and conventional freehand interstitial brachytherapy for locally advanced cervical cancer: a single-center retrospective study. PubMed 41952694
- Radiat Oncol, 2026 (senior author): Induction immunochemotherapy before definitive chemoradiotherapy versus definitive chemoradiotherapy alone in limited-stage small-cell lung cancer: a multicenter propensity score-matched analysis. PubMed 41808131
- J Cancer, 2026 (senior author): CES3 promotes NSCLC progression via lipid metabolic reprogramming regulated by TFAP2A. PubMed 41438579
- Hereditas, 2025 (senior author): LINC01980 promotes the malignant progression of lung squamous carcinoma by targeting miR-204-3p. PubMed 41390751
- Radiother Oncol, 2025 (senior author): Response to letter to the editor. PubMed 41052602
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion